All In Biotech

Drug Trial Radar · NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

May 16, 2033

Study completion Jan 26, 2038

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • PembrolizumabBiological

    IV Infusion

  • CisplatinDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Intismeran autogeneBiological

    IM injection

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS)Time frame: Up to ~97 months

Locations

247 sites in 31 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0181)

    Gilbert, Arizona · Recruiting

  • The University of Arizona Cancer Center - North Campus ( Site 0163)

    Tucson, Arizona · Recruiting

  • Providence St. Jude Medical Center ( Site 0106)

    Fullerton, California · Recruiting

  • VA Long Beach Healthcare System ( Site 0199)

    Long Beach, California · Recruiting

  • USC Norris Comprehensive Cancer Center ( Site 0205)

    Los Angeles, California · Recruiting

  • UCLA Jonsson Comprehensive Cancer Center ( Site 0135)

    Los Angeles, California · Recruiting

  • UCSF Medical Center at Mission Bay ( Site 0178)

    San Francisco, California · Recruiting

  • University of Colorado Anschutz Medical Campus ( Site 0151)

    Aurora, Colorado · Recruiting

  • UCHealth Memorial Hospital Central ( Site 0125)

    Colorado Springs, Colorado · Recruiting

  • Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)

    Greeley, Colorado · Recruiting

  • Centura Health - St. Anthony North Health Campus ( Site 0189)

    Westminster, Colorado · Recruiting

  • Yale University School of Medicine ( Site 0201)

    New Haven, Connecticut · Recruiting

  • Eastern CT Hematology & Oncology Associates ( Site 0202)

    Norwich, Connecticut · Recruiting

  • The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156)

    Fort Lauderdale, Florida · Recruiting

  • Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)

    Miami, Florida · Recruiting

  • Beacon Cancer Care ( Site 0127)

    Post Falls, Idaho · Recruiting

  • The University of Chicago Medical Center ( Site 0118)

    Chicago, Illinois · Recruiting

  • Hope and Healing Cancer Services ( Site 9527)

    Hinsdale, Illinois · Recruiting

  • Illinois Cancer Care ( Site 8107)

    Peoria, Illinois · Recruiting

  • Franciscan Health ( Site 0219)

    Indianapolis, Indiana · Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8102)

    Rockville, Maryland · Recruiting

  • Massachusetts General Hospital ( Site 0136)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Hospital ( Site 0155)

    Boston, Massachusetts · Recruiting

  • Ellis Fischel Cancer Center ( Site 0133)

    Columbia, Missouri · Completed

  • Lake Regional Hospital-Cancer Center ( Site 0123)

    Osage Beach, Missouri · Completed

  • Roswell Park Cancer Institute ( Site 0184)

    Buffalo, New York · Recruiting

  • Hematology-Oncology Associates of CNY ( Site 0164)

    East Syracuse, New York · Recruiting

  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216)

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai ( Site 0116)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0137)

    New York, New York · Recruiting

  • SUNY Upstate Cancer Center ( Site 0140)

    Syracuse, New York · Recruiting

  • Montefiore Medical Center ( Site 0160)

    The Bronx, New York · Recruiting

  • Westchester Medical Center ( Site 0196)

    Valhalla, New York · Recruiting

  • Novant Health Weisiger Cancer Insititute ( Site 0266)

    Charlotte, North Carolina · Recruiting

  • Novant Health Forsyth Medical Center ( Site 0166)

    Winston-Salem, North Carolina · Recruiting

  • University of Cincinnati Medical Center ( Site 0119)

    Cincinnati, Ohio · Recruiting

  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217)

    Corvallis, Oregon · Recruiting

  • St. Lukes Hospital and Health Network ( Site 0186)

    Bethlehem, Pennsylvania · Recruiting

  • Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315)

    Chattanooga, Tennessee · Recruiting

  • Thompson Cancer Survival Center ( Site 0168)

    Knoxville, Tennessee · Recruiting

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.